Aarhus Denmark – Jul 3, 2008 (PRN): Beijing Genomics Institute (BGI) has signed a global site license agreement for CLC bio’s Next Generation Sequencing solution, CLC Genomics Workbench. The site license covers all researchers at all BGI sites, both inside and outside of China.

Head of Bioinformatics Division at BGI, Ruiqiang Li states, ’We have chosen CLC Genomics Workbench as our platform for analyzing Next Generation Sequencing data after testing several commercial solutions, because it’s simply in a league of its own when it comes to flexibility and the way the Next Generation Sequencing tools can be used together with our own algorithms. In an organization of our size – with seventeen Illumina GA analyzers, as well as two AB/SOLiD and three Roche/454 Next Generation Sequencing machines, all of them running at full capacity – efficient workflows are of critical importance. We can support and expand our workflows by giving our scientists easy access via the Workbench to our own in-house developed algorithms. In no time, CLC Genomics Workbench has proved amazingly popular with our internal researchers, due to the fast, user-friendly and versatile platform it provides.’

Director of Partner Sales at CLC bio, Michael Heltzen states, ’We are most thrilled to have agreed on a global site license with one of the best bioinformatics and sequencing facilities in the world, less than four weeks after our solution for analyzing and visualizing Next Generation Sequencing data was released. Furthermore, we are honored that the famous bioinformatics researchers from BGI have chosen our Workbench as a working platform for both our and their own algorithms, side by side. CLC Genomics Workbench will help the scientists at BGI with their daily research, including prestigious projects like the Giant Panda Genome Project and the 1000 Genomes Project.’

CLC Genomics Workbench is the first comprehensive analysis package which can analyze and visualize data from all the major NGS platforms, such as Solexa by Illumina, SOLiD by Applied Biosystems, 454 by Roche Applied Science, and HeliScope by Helicos. CLC Genomics Workbench takes full advantage of “paired end” data and supports a number of features and work-tasks, such as reference assembly of genomes, de novo assembly of genomes, SNP detection using advanced models, multiplexing, and high-throughput trimming. Read more about it at: www.clcbio.com/genomics

CLC Genomics Workbench is available for Mac OS X, Windows and Linux.

About Beijing Genomics Institute

Beijing Genomics Institute is one of the leading global Genomics Institutes in the world, established in July 1999. Since then, BGI has grown rapidly and is partner in a number of international consortiums, including partnerships with the Wellcome Trust Sanger Institute, NIH and NHGRI on the 1,000 Genomes Project. BGI now has a number of research locations including major sites in Shenzhen and Beijing.

BGI aims to advance the understanding of biology and medicine through the use of large-scale sequencing and bioinformatics analysis. The institute also offers sequencing services to the international community. BGI promotes the use of genome-scale scientific approaches and strongly supports collaborative efforts in order to achieve this goal.

About CLC bio

CLC bio is the world’s leading full-service bioinformatics solution provider, solely focusing on the development of bioinformatics: software, hardware, data analysis, and custom-designed bioinformatics algorithms.

CLC bio’s mission is to be among the most innovative bioinformatics companies in the 21st century. This is realized through:

• Focusing on Next Generation Sequencing downstream data analysis

• Development of bioinformatics software and hardware based on the latest scientific findings

• User-friendly, integrated and intuitive cross-platform software solutions

• Continuous focus on customer needs and superior customer service

• Frequent product updates including the latest IT technologies and bioinformatics algorithms

• A flexible IT architecture, enabling customers to buy or develop individualized solutions at a reasonable price